Mar 28, 2024
Ionis to hold olezarsen Phase 3 data webcast
Mar 25, 2024
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Mar 13, 2024
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Feb 29, 2024
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Feb 28, 2024
Ionis to present at upcoming investor conferences
Feb 21, 2024
Ionis reports fourth quarter and full year 2023 financial results
Feb 15, 2024
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Feb 08, 2024
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Feb 07, 2024
Ionis to hold fourth quarter and full year 2023 financial results webcast
Jan 22, 2024
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Feb 11, 2021
Ionis to hold 2020 financial results webcast
Jan 05, 2021
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
Dec 08, 2020
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
Dec 02, 2020
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
Dec 01, 2020
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
Dec 01, 2020
Ionis to hold virtual investor day event
Nov 30, 2020
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
Nov 23, 2020
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
Nov 13, 2020
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
Nov 09, 2020
Ionis to present at upcoming virtual investor conferences